X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ABP-745 is an oral small molecule drug which is being evaluated for the treatment of acute gout. Preclinical trials showed that it can significantly reduce levels of inflammatory factors & compared with similar drugs, it has good efficiency & significant safety improvement.
Lead Product(s): ABP-745
Therapeutic Area: Rheumatology Product Name: ABP-745
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
The financing will be used for completion of global pivotal clinical trials of ABP-671, its unique orally administered URAT1 inhibitor for chronic gout and to advance to clinical stage the company’s innovative pipeline of drugs for inflammatory and metabolic diseases.
Lead Product(s): ABP-671
Therapeutic Area: Rheumatology Product Name: ABP-671
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kaitai Capital
Deal Size: $83.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing October 16, 2023
Details:
ABP-671 is a small molecule inhibitor of the urate transporter 1 (URAT1) protein, which is involved in the reabsorption of uric acid by the kidneys. In gout patients, ABP-671 reduces the reabsorption of uric acid, increasing its excretion in urine.
Lead Product(s): ABP-671
Therapeutic Area: Rheumatology Product Name: ABP-671
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
ABP-671 is a small molecule inhibitor of the urate transporter 1 (URAT1) protein, which is involved in the reabsorption of uric acid by the kidneys. In gout patients, ABP-671 reduces the reabsorption of uric acid, increasing its excretion in urine.
Lead Product(s): ABP-671
Therapeutic Area: Rheumatology Product Name: ABP-671
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
ABP-671 was well tolerated, with the overall incidence of treatment emergent adverse events similar between the ABP-671 treatment cohorts and the placebo cohorts.
Lead Product(s): ABP-671
Therapeutic Area: Rheumatology Product Name: ABP-671
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
Preliminary data suggest Atom’s compound ABP-671, a small molecule inhibitor of the urate transporter (URAT1) protein reduces uric acid levels to prevent gout flare-ups without the adverse side effects of existing treatments.
Lead Product(s): ABP-671
Therapeutic Area: Rheumatology Product Name: ABP-671
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
Funding will support company’s anticipated global Phase III clinical trial of lead product, ABP-671, for treatment of hyperuricemia and gout, which affects more than 255 million people worldwide.
Lead Product(s): ABP-671
Therapeutic Area: Rheumatology Product Name: ABP-671
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xicheng Jinrui Equity Investment Fund
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
